CJC-1295 no DAC - Livewell Pharmaceuticals

First described in 2005 by Jette et al., Mod GRF 1-29 is a tetrasubstituted peptide based on the active segment of human growth hormone releasing hormone (GHRH). Its design improves resistance to enzymatic breakdown while maintaining full biological function. Unlike CJC-1295, it lacks the Drug Affinity Complex (DAC), resulting in a much shorter duration of action. Despite this, Mod GRF 1-29 remains a preferred agent in combination GH therapy due to its selectivity and reduced risk of hormonal spillover effects.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about CJC-1295 no DAC by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.